Voxtur Bio

Thane, India Founded: 2013 • Age: 13 yrs Minicorn
Kits and reagents for in vitro diagnostics are developed.

About Voxtur Bio

Voxtur Bio is a Healthcare company based in Thane (India) founded in 2013. Kits and reagents for in vitro diagnostics are developed. Voxtur Bio has raised $3.16 million across 3 funding rounds from investors including Acumen Group, Ganesh Srinivasan and Equity Intelligence. The company has 14 employees. Voxtur Bio was last valued at $29.69 million in November 2019. Its Indian entity Voxtur Bio Limited reported revenue of β‚Ή51.38 Cr. Voxtur Bio offers products and services including VoxPress HIV 1 & 2 Rapid Card Test, VoxPress HCV Rapid Card Test, VoxSera Anti-A, VoxSera Anti-B, and VoxBank Widal 8 Antigen Slide Set. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Viral.

Company details

Voxtur Bio was founded in 2013 and is based in Thane, India. Operations focus on the in vitro diagnostics sector, where kits and reagents are developed for clinical use. VoxPress and VoxEl product lines are utilized as point-of-care and clinical immunoassays targeting infectious diseases, including HIV, HCV, toxoplasma, rubella, herpes, and CMV. Consumables and additional reagents for diagnostics are also produced.

  • Headquarters Thane, India
  • Employees 14
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website voxturbio.com
  • Social LinkedIn Facebook Instagram
  • Legal Name Voxtur Bio Limited
  • Date of Incorporation 06 Dec, 2012
  • Jurisdiction Vasai, Maharashtra, India
Operational Areas
Key Metrics
  • Annual Revenue
    ₹51.38 Cr

    FY 2024 · +38% YoY

  • Net Profit
    ₹4.55 Cr

    FY 2024 · 9% margin

  • EBITDA
    ₹9.95 Cr

    FY 2024 · 19% margin

  • Total Equity Funding
    $3.16M (USD)

    in 3 rounds

  • Latest Funding Round
    $1.6M (USD), Angel Round

    Nov 2019

  • Investors
  • Employee Count
    14

Products & Services of Voxtur Bio

Voxtur Bio offers a comprehensive portfolio of products and services, including VoxPress HIV 1 & 2 Rapid Card Test, VoxPress HCV Rapid Card Test, VoxSera Anti-A, VoxSera Anti-B, and VoxBank Widal 8 Antigen Slide Set.

VoxPress HIV 1 & 2 Rapid Card Test
Diagnostic Kit

Rapid test for detecting HIV 1 and 2 infections.

VoxPress HCV Rapid Card Test
Diagnostic Kit

Test for Hepatitis C virus detection.

VoxSera Anti-A
Blood Grouping Kit

Reagent for identifying blood type Anti-A.

VoxSera Anti-B
Blood Grouping Kit

Reagent for identifying blood type Anti-B.

VoxBank Widal 8 Antigen Slide Set
Diagnostic Kit

Slide set for typhoid fever antigen testing.

Funding Insights of Voxtur Bio

Voxtur Bio has successfully raised a total of $3.16M across 3 strategic funding rounds. The most recent funding activity was a Angel Round of $1.6 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $3.16M
  • Total Rounds 3
  • Last Round Angel Round β€” $1.6M
  • First Round $413,800

    (May 2016)

  • Investors Count 32

All 3 funding rounds of Voxtur Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2019$1.6MAngel Round$29.69MGanesh Srinivasan
–
Feb 2017$1.15MSeed$9.39MEquity Intelligence, Ganesh Srinivasan
May 2016$413,800Angel Round$β€’β€’β€’β€’β€’Hiren Shantilal Batavia
Valuation history
DateValuationStage
Nov 2019$29.69Mβ€’β€’β€’β€’β€’β€’β€’β€’
Feb 2017$9.39Mβ€’β€’β€’β€’β€’β€’β€’β€’
May 2016$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Premium access

Full valuation and stage history of Voxtur Bio

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $29.69M (Nov 2019). 32 investors in total: 3 institutional and 29 angel.

Investors in Voxtur Bio

Voxtur Bio has secured backing from 32 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Acumen Group, Ganesh Srinivasan and Equity Intelligence.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Multiple sectors are invested in by the private equity fund.
equityintelligence.comKochi, India
Online platform offering technical analysis solutions
2008acumengroup.inKochi, India
NovoMed is engaged in distributing advanced medical devices.
novomed.inMumbai, India

Ganesh Srinivasan

Angel investor, ex-Amazon and Flipkart leader, focused on tech startups
unknown_2187c616cad14fc39

Maheshwari Shrigopal Sunil

unknown_5161e6eb08fb4745b

Debashree Choudhary Chakraborty

unknown_317edcc7acba4eb9b

Leela Sunil Maheshwari

unknown_18c7191f68a2426f8

Anil Sarin

Angel investor, Chief Growth Officer at WhiteHat Jr, ex-Ola executive
unknown_bf724386df6d448da

Anik Chandrakant Shah

unknown_e7ecd7a645524ae99

Manish Kumar Jain

Angel investor, tech entrepreneur, and advisor in Indian startup ecosystem
unknown_9d369248e31149ec8
Premium access

Investor details for Voxtur Bio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Voxtur Bio Limited (Voxtur Bio)

Voxtur Bio Limited is the primary company behind Voxtur Bio. The board of Voxtur Bio Limited currently have 3 directors; the longest-serving is Veeraal Ramesh Gandhi, appointed in 2012. 12 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Veeraal Ramesh Gandhi
DIN 01450653
Managing Director06 Dec 201213 yrs 11 moVoxtur Bio Limited
Nikhil Dilipbhai Bhuta
DIN 02111646
Director01 Dec 20223 yrs 11 moVoxtur Bio Limited
Rajasekharan Bhaskaran Nair
DIN 00655414
CFO25 Sep 20242 yrs 1 moVoxtur Bio Limited

Financials of Voxtur Bio

Figures of Voxtur Bio Limited, the primary company behind Voxtur Bio, for FY 2024. Revenue was ₹51.38 Cr (+38% year on year). Net profit was ₹4.55 Cr (9% margin). EBITDA was ₹9.95 Cr (19% margin). Revenue has grown at a compounded annual rate of +11% over three years and +25% over five years.

  • ₹51.38 CrRevenue · FY 2024 · +38% YoY
  • ₹4.55 CrNet profit · 9% margin
  • ₹9.95 CrEBITDA · 19% margin
  • ₹6.37 CrPaid-up capital
  • 14Employees (provident fund records)
  • +11%Revenue CAGR, 3 years
  • +25%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Voxtur Bio Limited are on its company page.

Premium access

Detailed financial statements for Voxtur Bio

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Voxtur Bio

4 dated milestones of Voxtur Bio across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Voxtur Bio is founded.
  2. Funding First funding round of $414K.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Angel Round, of $1.6M.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Voxtur Bio

Premium access

Complete news archive for Voxtur Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Voxtur Bio

Voxtur Bio was founded in 2013 and raised its 1st funding round 3 years after it was founded.

Voxtur Bio is headquartered in Thane, India. It is registered at Thane, Maharashtra, India.

Voxtur Bio is a funded company, having raised a total of $3.16M across 3 funding rounds to date. The company's 1st funding round was a Angel Round of $413.8K, raised on May 2016.

Voxtur Bio has 14 employees.

The primary company behind Voxtur Bio, Voxtur Bio Limited, reported revenue of β‚Ή51.38 Cr for FY 2024, up 38% year on year.

Voxtur Bio was founded in 2013 and is based in Thane, India. Operations focus on the in vitro diagnostics sector, where kits and reagents are developed for clinical use. VoxPress and VoxEl product lines are utilized as point-of-care and clinical immunoassays targeting infectious diseases, including HIV, HCV, toxoplasma, rubella, herpes, and CMV. Consumables and additional reagents for diagnostics are also produced.

Voxtur Bio offers VoxPress HIV 1 & 2 Rapid Card Test, VoxPress HCV Rapid Card Test, VoxSera Anti-A, VoxSera Anti-B, and VoxBank Widal 8 Antigen Slide Set.

Voxtur Bio has 32 investors. Key investors include Acumen Group, Ganesh Srinivasan, Equity Intelligence, Maheshwari Shrigopal Sunil, and Debashree Choudhary Chakraborty.

The valuation of Voxtur Bio is $29.69M as of Nov 2019.

Voxtur Bio operates through Voxtur Bio Limited.

The legal entities of Voxtur Bio currently have 4 directors, including Nikhil Dilipbhai Bhuta, Veeraal Ramesh Gandhi, Rajasekharan Bhaskaran Nair and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available